Bloomfield Clara D, Mrózek Krzysztof, Caligiuri Michael A
Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3564s-71s. doi: 10.1158/1078-0432.CCR-06-9002.
The Cancer and Leukemia Group B (CALGB) Leukemia Correlative Science Committee (LCSC) has a remarkable history of outstanding productivity and has been at the cutting edge of correlative science for adult leukemia for almost 25 years. Its work, initially focused on the use of immunophenotyping for diagnosis and prognosis of acute lymphoblastic leukemia and acute myeloid leukemia, has, for the last 15 years, focused on the clinical use of cytogenetic and molecular genetic markers in acute myeloid leukemia and acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia. Numerous CALGB LCSC studies have had a major effect on the way we currently diagnose, predict outcome, select appropriate treatment, document complete remission, and monitor residual disease in adults with acute leukemia. In part as a result of the work of the CALGB LCSC, we are increasingly moving toward molecularly targeted therapy in acute and chronic leukemias. In this report, we briefly review those contributions from the CALGB LCSC that have had, or are likely to have in the future, a major effect on how we currently manage leukemia and outline directions of ongoing and future research conducted by the CALGB LCSC.
癌症与白血病B组（CALGB）白血病相关科学委员会（LCSC）有着卓越的历史，成果斐然，在成人白血病相关科学领域处于前沿近25年。其工作最初专注于利用免疫表型分析诊断和预测急性淋巴细胞白血病及急性髓细胞白血病，在过去15年里，聚焦于细胞遗传学和分子遗传学标志物在急性髓细胞白血病、急性淋巴细胞白血病以及慢性淋巴细胞白血病中的临床应用。CALGB LCSC的众多研究对我们目前诊断、预测预后、选择合适治疗方法、记录完全缓解情况以及监测成人急性白血病残留疾病的方式产生了重大影响。部分由于CALGB LCSC的工作，我们在急性和慢性白血病治疗中越来越倾向于分子靶向治疗。在本报告中，我们简要回顾CALGB LCSC做出的那些对我们目前白血病治疗方式已经产生或未来可能产生重大影响的贡献，并概述CALGB LCSC正在进行和未来研究的方向。
